A review of placebo-controlled trials in older adults separated acute balance effects from the cognitive outcomes measured.
What the source reports
Six articles were included, covering several zolpidem doses. The review found worse balance-related performance with zolpidem, while cognitive comparisons did not show a statistically significant difference. Zolpidem is a non-benzodiazepine hypnotic and should be identified as such when used as a comparator in benzodiazepine discussions.
Limits of the evidence
Trials were small and varied in dose, timing, and tests. Failure to detect a cognitive difference is not proof that all cognition is unaffected. Balance measures also do not directly establish a real-world fall rate.
Implications for forensic review
For an older-adult fall assessment, preserved performance on one cognitive task cannot exclude medication-related postural difficulty. Match the claimed effect to the measured domain and time after dosing. This review supports that distinction without proving the cause of an individual fall.
Source and related reading
Source reviewed: Cognitive and balance dysfunctions due to the use of zolpidem in the elderly a systematic review (PMC8485645). This article summarizes the supplied paper; forensic applications above are interpretive analysis.
Related reading: Catatonia in Anti-NMDA Receptor Encephalitis Persisted Despite a Clonazepam-Containing Regimen; Benzodiazepine Withdrawal Belongs in the Differential for Catatonia, but a Review Cannot Diagnose the Case.
Leave a Reply